Sonnet BioTherapeutics (SONN) said Monday it has agreed to merge with Rorschach, backed by Atlas Merchant Capital and Paradigm Operations and will build a reserve of HYPE, the token of the Hyperliquid Layer-1 blockchain.
Sonnet said the new entity, Hyperliquid Strategies (HSI), will hold 12.6 million HYPE tokens valued at $583 million and receive at least $305 million in cash, valuing the deal at $888 million.
HSI will be listed on Nasdaq under a new ticker and operate as a public cryptocurrency treasury company, with strategic investors including Paradigm, Galaxy Digital, Pantera Capital, D1 Capital, Republic Digital, and 683 Capital.
Parallely, Sonnet said it plans to raise $5.5 million via private placement of convertible preferred stock and warrants, closing July 14.
A $2 million convertible note from June will convert at closing. Funds will support corporate operations, biotech development, and transaction costs, it added.
Following the business combination, Sonnet said it will become a wholly owned subsidiary of Hyperliquid Strategies and continue developing its biotech asset SON-1010, its lead candidate for cancer immunotherapy, while divesting other holdings.
Common shareholders and certain equity holders will receive a contingent value right at closing it said, adding that it is also pursuing commercial partnerships for its biotech portfolio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.